Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CD34 is a marker for isolating stem-like cells in mouse hair follicles.

This study found that androgenetic alopecia may involve a defect in the conversion of hair follicle stem cells to progenitor cells, as demonstrated by a reduced presence of progenitor cells in bald scalp samples.

This study found that CD34 is necessary for TPA-induced activation of hair follicle stem cells and tumor formation in mice, with CD34 knockout mice showing delayed and reduced tumor development compared to wild-types.

This study found that interfollicular injection of autologous CD34+ cell-containing PRP preparation improved hair count and thickness in patients with pattern hair loss, with better results than placental extract treatment.

This study found that in scarring alopecia, stem cells are differentially localized, suggesting that both inner and outer root sheath stem cells, rather than just follicular bulge stem cells, are involved.

This study found that CD34- melanocyte stem cells regenerated pigmentation more efficiently, while CD34+ cells showed potential for neuron myelination, suggesting different therapeutic applications for each population.

This study identified that bone marrow-derived CD34⁺ cells act as fibroblast progenitors to enhance tissue regeneration in ischemic limbs by promoting angiogenesis through interactions with macrophages.

This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.

This study observed dynamic changes in CD10 and CD34 expression in fetal and adult human hair follicles during embryogenesis and hair cycling.

In this study, researchers reported that CD34 expression in the isthmic region of canine hair follicles suggests a potential stem cell compartment in this area.

This study found that the presence of CD3(+) T-cells within empty follicular fibrous tracts is a reliable indicator for diagnosing diffuse alopecia areata instead of pattern hair loss.

Hair follicle stem cells can become neural cells using different methods, with varying efficiency.

This study concluded that CD36-expressing dermal sheath cells may influence the modulation of blood capillaries in hair follicles, potentially affecting hair cycling.

This study found that CD34+ cells from adipose tissue may enhance hair morphogenesis and participate in blood vessel formation in reconstituted skin tissues of mice.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

This study investigated the heterogeneity of CD34+ cells in wound healing, identifying distinct cell clusters and suggesting potential therapeutic approaches for anagen and diabetic wounds.

This study found that immunohistochemistry can effectively distinguish between tricholemmoma and basal cell carcinoma, with BerEP4 and CD34 serving as key differentiators.

This chapter reviews the methodology for isolating and differentiating CD34+ HAP stem cells into neural cells, but provides no new research results.

This study detected higher expression of p63 in occipital scalp areas compared to frontal areas, with minimal changes in beta-catenin expression and a novel finding of CD34 positive cells in hair follicles' outer root sheath.

In this study, one type of commercial culture medium supported expression of stem cell markers in hair follicle epithelial stem cells, but their differentiation potential and hair follicle-inducing ability declined over time.

In this study, nondermal-derived CD34+ cells from adult peripheral blood were found to enhance wound healing and contribute to hair follicle neogenesis and skin regeneration.

This study observed that alopecia areata patients had significantly lower levels of hair follicle stem cell markers SOX9 and CD34 in affected skin samples, correlating with disease severity and recurrence, suggesting potential impairment in hair regeneration.

This study confirms that human CD34+ melanocyte stem cells can be differentiated into melanin-producing cells, suggesting potential for cellular therapy in treating skin degenerative diseases.

This study observed that in androgenetic alopecia patients, the expression of CD34+ progenitor cells significantly decreased in frontal scalp biopsies, while Sox9 expression remained consistent, suggesting that altered conversion of hair follicle stem cells to progenitors may significantly contribute to AGA development.

In this study, researchers documented the immunohistochemical distribution of CD34 in basal cell carcinoma and found distinct patterns of CD34 expression, with variations in CD34 positivity between different areas of BCC tumor stroma and adjacent skin regions.

This study found that platelet-rich plasma therapy significantly improved hair density, diameter, and reduced inflammation in androgenetic alopecia patients compared to placebo, though individual responses varied.

This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stem cell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.

In this study, the researchers developed a quantum algorithm, QuantAnts machines, which identified complexes of CD9, CD34, and CD74 as potential targets for certain cancers involving the RAS pathway.

This study found that patients with Alopecia areata in Iraq had significantly higher levels of CD4+, CD39+, and FOXP3+ Treg cells in their blood compared to healthy controls.

This study found that TriCell CD34 + cell-containing PRP injections improved hair thickness and density in patients with alopecia after three months of treatment, with no special side effects reported.